

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived human IL-10 R alpha protein		
	Human IL-10 R alpha (His22-Asn235) Accession # Q13651.2	Avi-tag	6-His tag
	N-terminus		C-terminus
N-terminal Sequence	His22		
Analysis			
Structure / Form	Biotinylated via Avi-tag		
Predicted Molecular Mass	28 kDa		

SPECIFICATIONS


SDS-PAGE	40-55 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA. Recombinant Human IL-10 R α Avi-tag His-tag (Catalog # AV111459) binds Recombinant Human IL-10 (Catalog # 1064-ILB) with an ED ₅₀ of 8.00-96.0 ng/mL.
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 400 μ g/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Binding Activity



Recombinant Human IL-10 R α Avi-tag His-tag Protein Binding Activity. Recombinant Human IL-10 R α Avi-tag His-tag Protein (Catalog # AV111459) binds Recombinant Human IL-10 (Catalog # 1064-ILB) with an ED₅₀ of 8.00-96.0 ng/mL.

SDS-PAGE



Recombinant Human IL-10 R α Avi-tag His-tag Protein SDS-PAGE. 2 μ g/lane of Recombinant Human IL-10 R α Avi-tag His-tag Protein (Catalog # AV111459) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 40-55 kDa, under reducing conditions.

BACKGROUND

Interleukin-10 Receptor alpha (IL-10 R α), also known as IL-10 R1, is a 90-110 kDa transmembrane glycoprotein member of the class II cytokine receptor family (1). IL-10 R α is required for mediating the effects of IL-10, a critical molecule in the control of microbial infections, allergic and autoimmune inflammation, and cancer (2-5). Whereas human IL-10 is active on mouse cells, mouse IL-10 does not act on human cells (6). IL-10 R α is the ligand specific subunit of the IL-10 receptor complex. Noncovalent dimers of IL-10 bind to IL-10 R α , resulting in the recruitment of IL-10 R β (6-8). IL-10 R β is a ubiquitously expressed transmembrane protein that does not bind IL-10 by itself but is required for signal transduction and *in vivo* IL-10 responsiveness (7, 9). IL-10 R β also associates with IL-20 R α , IL-22 R α , or IL-28 R α to form the receptor complexes for IL-22, IL-26, IL-28, and IL-29 (1). Immunosuppressive signal transduction through the IL-10 receptor complex can be inhibited by activation of TLR2, 4, or 9, enabling strengthened immune responses during infection (10). Polymorphisms of human IL-10 R α may limit viral immune evasion by retaining full responsiveness to human IL-10 but responding weakly to the cytomegalovirus homolog of IL-10 (11). Mature human IL-10 R α consists of a 214 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 322 aa cytoplasmic domain (12). Within the ECD, human IL-10 R α shares 59% aa sequence identity with mouse and rat IL-10 R α . Our Avi-tag Biotinylated human IL-10R α features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References:

1. Pestka, S. *et al.* (2004) *Annu. Rev. Immunol.* **22**:929.
2. Manzanillo, P. *et al.* (2015) *Trends Immunol.* **36**:471.
3. Sziksz, E. *et al.* (2015) *Mediators Inflamm.* **2015**:764641.
4. Mannino, M.H. *et al.* (2015) *Cancer Lett.* **367**:103.
5. Fitzgerald, D.C. *et al.* (2007) *Nat. Immunol.* **8**:1372.
6. Tan, J.C. *et al.* (1993) *J. Biol. Chem.* **268**:21053.
7. Kotenko, S.V. *et al.* (1997) *EMBO J.* **16**:5894.
8. Tan, J.C. *et al.* (1995) *J. Biol. Chem.* **270**:12906.
9. Spencer, S.D. *et al.* (1998) *J. Exp. Med.* **187**:571.
10. Fernandez, S. *et al.* (2004) *J. Immunol.* **172**:2613.
11. Gruber, S.G. *et al.* (2008) *Eur. J. Immunol.* **38**:3365.
12. Liu, Y. *et al.* (1994) *J. Immunol.* **152**:1821.